literature

HIV mutation literature information.

HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.

PMID: 34762770 2021 Journal of the International AIDS Society

Result: Amino acid changes, including G335D, N348I, T369I, A371V, and A376S associated with DPV or NNRTI resistance were not detected in the connection or RNAse H domains of HIV-1 RT.

Table: N348I

Distribution characteristics of drug resistance mutations of HIV CRF01_AE, CRF07_BC and CRF08_BC from patients under ART in Ganzhou, China.

PMID: 34402512 2021 The Journal of antimicrobial chemotherapy

Abstract: The most common DRMs of these three subtypes were K103N and M184V, while the mutation frequencies of M41L, D67N, K70R, K101E, V106M, Y181C, K219E, H221Y and N348I were obviously different among subtypes.

Analysis and Molecular Determinants of HIV RNase H Cleavage Specificity at the PPT/U3 Junction.

PMID: 33477685 2021 Viruses

Abstract: Nonnucleoside RT inhibitors (NNRTIs) can interfere with the initiation of plus-strand DNA synthesis by enhancing PPT removal, while HIV RT connection subdomain mutations N348I and N348I/T369I mitigate this effect by altering RNase H cleavage specificity.

Abstract: The combination N348I/T369I in HIV-1BH10 RT has a dominant effect on the RNase H cleavage specificity at the PPT/U3 site.

Introduction: In a previous study, we showed that amino acid substitutions in the connection subdomain of HIV-1 RT such as N348I and T369I affect the rigidity of a hypot

HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.

PMID: 32555643 2020 PloS one

Method: N348I) that may impact on ARV drug susceptibility.

HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naive HIV-infected individuals.

PMID: 32119691 2020 PloS one

Table: N348I

High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.

PMID: 32105319 2020 The Journal of antimicrobial chemotherapy

Table: N348I

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.

PMID: 29566538 2018 Antiviral chemistry & chemotherapy

Method: Resistance mutations in the connection and RNAse H domains of RT spanning amino acids 320-560 included Y318F (3%) and N348I (14%).

High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.

PMID: 28750647 2017 AIDS research and therapy

Introduction: Specifically, V106M (NNRTI), K65R (NRTI) and N348I are more common among subtype C strains compared to other group M strains.

Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults.

PMID: 28328546 2017 Journal of acquired immune deficiency syndromes (1999)

Result: Although most mutations in plasma and CSF were similar, 2 of 3 LLV cases had unique mutations in CSF (case 1: D67N, N348I, E399D, K20R; case 2: P225L, T74A).

Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.

PMID: 26850643 2016 Nucleic acids research

Result: E312Q, G335C/D, N348I, A360I/V, V365I and A376S) have been identified that significantly contribute to AZT resistance by reducing RNase H activity.

Browser Board

Co-occurred Entities

Filtrator